Infinitus Systems vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI voice automation platform handling healthcare phone calls — benefits verification, prior auth, and referrals — at scale. San Francisco CA; raised $52M+ (a16z, GV);
About
Infinitus Systems is a healthcare AI company that automates the high-volume, repetitive phone call work that burdens provider administrative teams. Founded in 2019 and headquartered in San Francisco, California, Infinitus has raised more than $52 million from investors including Andreessen Horowitz and GV. The company's AI voice agent, called Maya, conducts real-time phone conversations with insurance payers to verify benefits, check prior authorization status, confirm referrals, and gather other eligibility information on behalf of healthcare providers.\n\nTraditionally, benefits verification and prior authorization follow-up requires large teams of staff members spending hours on hold and navigating complex phone trees. Infinitus replaces this manual process with an AI agent that operates around the clock, completing calls faster than human agents and capturing structured data directly into provider workflows. Customers include health systems, specialty practices, revenue cycle management outsourcers, and digital health companies that need to scale patient access operations without proportionally growing headcount.\n\nThe platform is designed for interoperability, delivering results through APIs and direct integrations with EHR systems, practice management software, and RCM platforms. Infinitus has processed tens of millions of healthcare transactions and continues to expand the scope of calls its AI can handle, with a roadmap that includes scheduling, referral coordination, and patient-facing outreach.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.